S564
Clinical – Head & neck
ESTRO 2026
retrospective analysis was conducted at a single institution including consecutive patients with head and neck cancer undergoing concomitant chemoradiotherapy, who received daily PBM throughout their treatment. Toxicities were assessed at four key time points: T1, PBM initiation (mean day 14 from radiotherapy start); T2, day 15 of PBM (mean day 28.6); T3, completion of PBM (mean day 46.6); and T4, six weeks post-radiotherapy (mean day 89.4). Results:
Conclusion: MRI-based radiomics models significantly outperformed both clinical-only and CT-based radiomics models in predicting key outcomes for NPC, particularly in LC and LRC. These models improve risk stratification and may support more individualised treatment decisions. Keywords: Nasopharyngeal carcinoma, outcome prediction Integrating Photobiomodulation into Standard Chemoradiotherapy: A Novel Approach to Toxicity Prevention in Head and Neck Cancer Elsa El Rawadi 1,2 , Houssam El Masri 1 , Filippo Dall Olio 1 , Roger Sun 2 , Yungan Tao 2 , France Nguyen 2 , Camelia Billard 2 1 Department of medical oncology, Gustave Roussy cancer institute, Villejuif, France. 2 Department of radiotherapy, Gustave Roussy cancer institute, Villejuif, France Digital Poster 1271 Purpose/Objective: This study aimed to evaluate the effectiveness of a daily photobiomodulation (PBM) protocol in preventing and reducing chemoradiotherapy-induced toxicities—including dysphagia, radiodermatitis, and oral mucositis—in patients undergoing treatment for head and neck cancer, thus improving overall tolerance and quality of life. Material/Methods: Between October 2024 and August 2025, a
Made with FlippingBook - Share PDF online